Revision history of "DEVELOPMENT OF AN INNOVATIVE PROGNOSTIC APPROACH FOR PATIENTS WITH LUNG CANCER: FOCUS ON THE THERAPY — IMMUNEPHARMA SRL" (Q2024033)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 March 2024

14 June 2023

12 June 2023

26 April 2023

8 April 2023

5 July 2022

  • curprev 01:2301:23, 5 July 2022DG Regio talk contribs 56,534 bytes +37,288 Changed label, description and/or aliases in da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et, nl, fr, de, es, and other parts: Adding translations: da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et,

10 February 2022

24 January 2022

24 December 2021

23 December 2021

14 December 2021

29 December 2020

2 November 2020

16 July 2020

8 June 2020

24 March 2020

  • curprev 12:5412:54, 24 March 2020DG Regio talk contribs 10,243 bytes +1,283 Created claim: summary (P836): Objective ÃO UPDATE, TRAMITE DIAGNOSTICI * individual * FOR DIAGNOSTIC PRODUCTS * ONLY FOR THE BENEFITS OF THE FIRST AND THE BENEFIT OF THE FIRST AND THE TEST, THE END OF THE PROPOSED BY THE TREATMENT, TO THE PROMOTION OF PEOPLE’S TERTIVATION. THE IMPH MUST CARRY OUT THE IDENTIFICATION OF BIOMARKER, CASPASI-4, WHICH HAS A HIGH DIAGNOSTIC POWER, ACCORDING TO THE SCIENTIFIC DATA ESTABLISHED DURING THE RESEARCH AND DEVELOPMENT ACTIVITIES, AT PLASMA...
  • curprev 04:2804:28, 24 March 2020DG Regio talk contribs 8,960 bytes +433 Changed an Item

19 March 2020

12 March 2020

6 March 2020